55
Views
0
CrossRef citations to date
0
Altmetric
Meeting Report

Ion Channels In Drug Discovery and Development

Pages 1651-1654 | Published online: 24 Feb 2005

Bioliography

  • WEN H, LEVITAN TB: Calmodulin is an auxiliary subunit of KCNQ2/3 potassium channels. J. Neurosci. (2002) 22(18):7991–8001.
  • ARKIN MR, WELLS JA: Small-molecule inhibitors of protein-protein interactions: progression towards the dream. Nature Rev Drug Discov. (2004) 3(4):301–317.
  • BERNARD C, ANDERSON A, BECKER A, POOLOS NP, BECK H, JOHNSTON D: Acquired dendritic0 channelopathy in temporal lobe epilepsy. Science (2004) 305(5683):532–535.
  • QUIRK JC, NISENBAUM ES: Multiple molecular determinants for allosteric modulation of alternatively spliced AMPA receptors. J. Nearest". (2003) 23(34):10953–10962.
  • STAATS PS, YEARWOOD T, CHARAPATA SG et al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomised controlled trial. JAMA (2004) 291(1):63–70.
  • FDA 21 CFR Part 11. Federal Register. (1997) 62(54):13430–13466.
  • FERMINI B, FOSSA AA: The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev Drug Discov. (2003) 2(6):439–447. Affiliation Emanuele Sher MD Eli Lilly and Co., Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey, GU20 6PH, UK Tel: +44 1276 483458; Fax: +44 1276 483525; E-mail: [email protected]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.